Search
01/01/2023
Quality of life of patients with stone disease: timing, planning, strategies, and prevention of a systemic pathology
Esperto F., Pietropaolo A., Emiliani E., de Coninck V., Tailly T., Keller E.X., Talso M., Tonyali S., Sener E.T., Zeeshan Hameed B.M., Tzelves L., Ventimiglia E., Juliebø-Jones P., Faiella E., Mykoniatis I., Tsaturyan A., Scarpa R.M.. Quality of life of patients with stone disease: timing, planning, strategies, and prevention of a systemic pathology. Minerva Urology And Nephrology. 2023; 75(4)DOI:10.23736/S2724-6051.23.05435-6. PMID:37314814. IF:4.900(Q1/2D).
01/01/2023
Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure
Sanz Gómez I., Huguet J., Bravo A., Robalino J., Rodríguez Faba Ó., Territo Á., Gaya J.M., Palou J., Breda A.. Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. Clinical Genitourinary Cancer. 2023; 21(4)DOI:10.1016/j.clgc.2023.03.002. PMID:37076337. IF:2.300(Q2/5D).
01/01/2023
A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer
Grobet-Jeandin E., Lenfant L., Mir C., Giannarini G., Alcaraz A., Albersen M., Breda A., Briganti A., Rouprêt M., Seisen T., EAU Section of Oncological Urology (ESOU) Board. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. European Urology Oncology. 2023; 6(3)DOI:10.1016/j.euo.2023.02.008. PMID:36906510. IF:8.300(Q1/1D).
01/01/2023
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients with Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study
Tyson M.D., Morris D., Palou J., Rodriguez O., Mir M.C., Dickstein R.J., Guerrero-Ramos F., Scarpato K.R., Hafron J.M., Messing E.M., Cutie C.J., Maffeo J.C., Raybold B., Chau A., Stromberg K.A., Keegan K.A.. Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients with Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study. JOURNAL OF UROLOGY. 2023; 209(5)DOI:10.1097/JU.0000000000003195. PMID:37026631. IF:6.400(Q1/1D).
01/01/2023
Native nephrectomy and arterial embolization of native kidney in autosomal dominant polycystic kidney disease patients: indications, timing and postoperative outcomes
Prudhomme T., Boissier R., Hevia V., Campi R., Pecoraro A., Breda A., Territo A.. Native nephrectomy and arterial embolization of native kidney in autosomal dominant polycystic kidney disease patients: indications, timing and postoperative outcomes. Minerva Urology And Nephrology. 2023; 75(1)DOI:10.23736/S2724-6051.22.04972-2. PMID:36094388. IF:4.900(Q1/2D).
01/01/2023
The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma
Gallioli A., Basile G., Territo A., Verri P., Gaya J.M., Sanguedolce F., Aumatell J., Izquierdo P., Uleri A., Diana P., Huguet J., Algaba F., Palou J., Breda A.. The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma. WORLD JOURNAL OF UROLOGY. 2023; 41(10)DOI:10.1007/s00345-023-04577-8. PMID:37668716. IF:2.800(Q2/3D).